Lucknow: Chandan Healthcare Limited (NSE – CHANDAN), – Chandan Healthcare Limited, one of the leading players in Diagnostic sector having Pan India presence, has announced its unaudited Financial Results for Q2 & H1 FY27.
Standalone Key Financial Highlights:
Q2 FY27 Standalone Key Financial Highlights
- Total Income: ₹59.36 Cr, up 44.78% YoY and 19.30% QoQ
- EBITDA: ₹22.12 Cr, up 54.79% YoY and 21.57% QoQ
- EBITDA Margin: 37.26%, up 241 BPS YoY and 69 BPS QoQ
- PAT: ₹18.61 Cr, up 224.19% YoY and 175.45% QoQ
- PAT Margin: 31.35%, up 1,735 BPS YoY and 1,777 BPS QoQ
- EPS: ₹6.44, up 226.90% YoY and 175.21% QoQ
H1 FY27 Standalone Key Financial Highlights
- Total Income: ₹109.12 Cr, up 40.56% YoY
- EBITDA: ₹40.31 Cr, up 66.52% YoY
- EBITDA Margin: 36.95%, up 576 BPS YoY
- PAT: ₹25.37 Cr, up 256.72% YoY
- PAT Margin: 23.25%, up 1,409 BPS YoY
- EPS: ₹8.78, up 122.84% YoY
Note: Chandan Healthcare Limited divested its entire stake in Chandan Pharmacy Limited during Q2 FY27. The Standalone results therefore reflect the Company’s diagnostics business and are the basis for comparison going forward. PAT, PAT margin and EPS for Q2 FY27 and H1 FY27 include a one-time exceptional gain of ₹10.23 Cr (net of tax; ₹12.03 Cr gross) on the sale of the Company’s investment in equity shares of Chandan Pharmacy Limited. EBITDA and PAT margins are calculated on Total Income. EPS is basic EPS. Comparative figures are as presented in the results filed with the exchange.
Commenting on the financial performance, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, said, “Q2 FY27 was a strong quarter for us. Consolidated total income grew 48.70% year-on-year and EBITDA grew 63.35%, with EBITDA margin up 331 basis points. For the half year, total income grew 35.69% and EBITDA grew 49.03%. The growth came from our diagnostics business as the franchise network scaled up.
Our franchise network grew from 264 centres at the end of June to 685 centres at the end of September. Franchising lets us widen our reach in a capital-efficient manner, and we continue to work towards 1,000 franchise centres. We also added Comprehensive Diagnostic Centres, Diagnostic Centres and Labs of our own during the quarter.
In August, the Board approved the sale of our entire stake in Chandan Pharmacy Limited, and the transaction was completed during the quarter. Pharmacy was a low-margin business, with over 70% of its revenue coming from B2B supply. The sale lets us put management time and capital behind diagnostics, which earns materially higher margins, and the proceeds will go towards new diagnostic centres. PAT for the quarter includes a one-time gain from the sale, so profit growth should be read with that in mind.
For the rest of FY27, we will keep adding franchise centres towards the 1,000 mark, open owned centres in attractive markets, scale our work with Jeena Sikho hospitals and clinics and grow the B2G business. We will put capital where returns are higher, which means new diagnostic centres, and keep improving utilisation across the network.”







Leave a Reply